ArticleClinical & developmental immunology2012
Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.
Article in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Systematic review-pancreatic involvement in inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2022Pooled it
- Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis.World journal of gastroenterology · 2020Pooled it
- Diagnostic value of the antiglycoprotein-2 antibody for Crohn's disease: a PRISMA-compliant systematic review and meta-analysis.BMJ open · 2017Pooled it
- Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.PloS one · 2018Trial
- Pancreatic Exocrine Insufficiency Is Surprisingly Common.Integrative medicine (Encinitas, Calif.) · 2026Article
- Crohn's Disease-Associated Granulomatous Pancreatitis With Exocrine Pancreatic Insufficiency.ACG case reports journal · 2024Article
- Serum Biomarkers for Inflammatory Bowel Disease.Frontiers in medicine · 2020Review
- Pancreatic endosonographic findings and clinical correlation in Crohn's disease.Clinics (Sao Paulo, Brazil) · 2019Article
- Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Article
- Pancreatic Involvement in Inflammatory Bowel Disease: A Review.Journal of clinical medicine research · 2018Review
- Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.Clinical and translational gastroenterology · 2018Article
- Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.Inflammatory bowel diseases · 2016Article
- Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.Medicine · 2015Observational
- Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.Gastroenterology · 2015Review
- Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.World journal of gastroenterology · 2015Article
- Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn's disease.BMC gastroenterology · 2014Article
- New serological markers in pediatric patients with inflammatory bowel disease.World journal of gastroenterology · 2014Review
- The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.Gastroenterology research and practice · 2013Article
- CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.Clinical & developmental immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Why zymogen glycoprotein 2 (GP2), the Crohn's disease (CD)-specific pancreatic autoantigen, is the major target of humoral autoimmunity in inflammatory bowel diseases (IBD) is uknown. Recent evidence demonstrates that GP2 is also present on the apical surface of microfold (M) intestinal cells. As the colon lacks GP2-rich M cells, we assumed that patients with colonic CD are seronegative for anti-GP2. Anti-GP2 antibodies were tested in 225 CDs, including 45 patients with colonic location (L2), 45 with terminal ileum (L1) and 135 with ileocolonic involvement; 225 patients with ulcerative colitis (UC) were also tested. Anti-GP2 reactivity was detected in 59 (26.2%) CDs and 15 (6.7%) UCs (P < 0.001). Only 5 CDs with L2 had anti-GP2 antibodies, compared to 54/180 (30.0%, P = 0.0128) of the CDs with L1 and L3. Anti-GP2 antibody positive CD patients had higher ASCA titres compared to seronegative cases. Amongst the 128 CD patients with previous surgical intervention, 45 (35.0%) were anti-GP2 antibody positive compared to 14/97 (14.0%) without surgical (P < 0.001). Our data support the assumption that ileal inflammation is required for the development of anti-GP2 antibodies in CD, and suggest that the intestine rather than the pancreatic juice is the antigenic source required for the initiation of anti-GP2 antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.